Gyre Therapeutics (GYRE) Net Cash Flow (2010 - 2026)
Gyre Therapeutics (GYRE) reported Net Cash Flow of $166000.0 for Q1 2026, down 94.78% year-over-year from $3.2 million in Q1 2025, and up 104.83% quarter-over-quarter from -$3.4 million in Q4 2025.
Gyre Therapeutics (GYRE) Net Cash Flow (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has 17 years of Net Cash Flow data on file, last reported at $166000.0 in Q1 2026.
- Net Cash Flow for Q1 2026 came in at $166000.0, down 94.78% year-over-year; the trailing twelve-month figure through Mar 2026 was $21.9 million (up 250.3% YoY), and the FY2025 annual result was $24.9 million, up 216.25% from the prior year.
- Net Cash Flow rose to $166000.0 in Q1 2026 per GYRE's latest filing, from -$3.4 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $40.6 million in Q2 2022 and troughed at -$52.3 million in Q3 2022.
- A 5-year average of -$2.1 million and a median of -$3.4 million in 2025 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2022 and 2025: Net Cash Flow slumped 261.62% in 2022, then soared 1203.26% in 2025.
- A 5-year view of Net Cash Flow shows it stood at -$26.9 million in 2022, then soared by 174.15% to $19.9 million in 2023, then tumbled by 119.05% to -$3.8 million in 2024, then climbed by 9.58% to -$3.4 million in 2025, then jumped by 104.83% to $166000.0 in 2026.
- Business Quant data shows GYRE's Net Cash Flow at $166000.0 in Q1 2026, -$3.4 million in Q4 2025, and $3.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 2.44 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 625.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.44 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 457.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 664,983.53 |
| 10 | Gyre Therapeutics | 554.75 Mn | 540.62 Mn | 8.38 Mn | 166,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 166,000.00 |
| Mar 31, 2026 | 166,000.00 |
| Dec 31, 2025 | -3.43 Mn |
| Dec 31, 2025 | -3.43 Mn |
| Sep 30, 2025 | 3.72 Mn |
| Sep 30, 2025 | 3.72 Mn |
| Jun 30, 2025 | 21.44 Mn |
| Jun 30, 2025 | 21.44 Mn |
| Mar 31, 2025 | 3.18 Mn |
| Mar 31, 2025 | 3.18 Mn |
| Dec 31, 2024 | -3.80 Mn |
| Dec 31, 2024 | -3.80 Mn |
| Sep 30, 2024 | -337,000.00 |
| Sep 30, 2024 | -337,000.00 |
| Jun 30, 2024 | -13.61 Mn |
| Jun 30, 2024 | -13.61 Mn |
| Mar 31, 2024 | -3.68 Mn |
| Mar 31, 2024 | -3.68 Mn |
| Dec 31, 2023 | 19.94 Mn |
| Dec 31, 2023 | 19.94 Mn |